Search

Your search keyword '"Weng, H."' showing total 50 results
Start Over Author "Weng, H." Publisher elsevier bv
50 results on '"Weng, H."'

9. Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life

Author

Hong Qiu, Choosak Pripatnanont, Maximiliano van Kooten Losio, Y. Liu, Weng H. Chow, Azad Hassan Abdul Razack, Grace K.M. Low, Edmund Chiong, Ji Y. Lee, Hirotsugu Uemura, Sudhir Rawal, Yeong S. Pu, and Dingwei Ye

Subjects
Quality of life, Registry, medicine.medical_specialty, Asia, Urology, Population, 030232 urology & nephrology, Disease, lcsh:RC870-923, 03 medical and health sciences, 0302 clinical medicine, Disease registry, medicine, Overall survival, education, education.field_of_study, Prostate cancer, business.industry, Clinical study design, Incidence (epidemiology), lcsh:Diseases of the genitourinary system. Urology, 030220 oncology & carcinogenesis, Cohort, Emergency medicine, Original Article, Observational study, business
Abstract

Background: The incidence of prostate cancer (PC) in Asian countries is increasing for reasons that are not clear. Data describing how PC is diagnosed and treated are fragmented across Asia, with marked intercountry and intracountry differences in outcome and knowledge gaps in clinical diagnostic and treatment practices. To address these knowledge gaps, we have established a PC disease registry with the aim of providing a comprehensive picture of PC diagnosis, prognosis, treatment and outcome, population characteristics, and comorbidities in real-world clinical practice in Asia. Methods: This is a multinational, multicenter, longitudinal, and observational registry of PC patients presenting to participating tertiary-care hospitals in eight Asian countries (www.clinicaltrials.gov NCT02546908. Registry Identifier: NOPRODPCR4001). Approximately 3500-4000 eligible patients with existing or newly diagnosed high-risk localized PC (cohort 1), nonmetastatic biochemically recurrent PC (cohort 2), or metastatic PC (cohort 3) will be consecutively enrolled and followed-up for 5 years. An enrollment cap of 600 patients each will be applied to cohorts 1 and 2. Disease status is collected at enrollment, and outcome variables captured at 3-monthly intervals include diagnostic/staging, treatments including reason for change, laboratory results, comorbidities, and concomitant medications. Treatments and survival outcomes will be captured real time until study end. Patient-reported quality-of-life will be measured every 6 months, and medical resource utilization summarized at study end. Data analysis will include exploratory analyses of potential associations between multiple risk factors and socioeconomic variables with disease progression and evaluation of various treatments for PC including novel therapies on clinical outcome and health-related quality-of-life outcomes. Results: 3636 men with PC were enrolled until July 2018; 416 in cohort 1, 399 in cohort 2 and 2821 in cohort 3. Discussion: A total of 3636 patients were enrolled until July 2018. The prospective disease registry will provide comprehensive and wide-ranging real-world information on how PC is diagnosed and treated in Asia. Such information can be used to inform policy development for best practice and direct clinical study design evaluating new treatments. Keywords: Asia, Overall survival, Prostate cancer, Quality of life, Registry

Published
2019

10. Long-Term Clinical Sequelae and Immunological Features of COVID-19 Survivors: A Cross-Sectional Study in Wuhan, China

Author

He Z, Lin M, Qi Wang, Zhou X, Weng H, Huang L, Zheng G, Wei Wang, Hu J, Xiaohong Ruby Xu, Banghan Ding, Xi X, Lin Q, Hao Liu, Linda L. D. Zhong, Y Zhang, Zhongde Zhang, Ye W, Yungui Wang, Ling Zhang, J. Y. Zhang, Jianwen Guo, Danwen Zheng, Yufeng Liu, and Feng B

Subjects
medicine.medical_specialty, Vital capacity, Rehabilitation, Cross-sectional study, business.industry, medicine.medical_treatment, Medical record, Pulmonary function testing, Informed consent, DLCO, Internal medicine, medicine, business, Psychosocial
Abstract

Objectives: To describe the clinical sequelae and immunological features of COVID-19 survivors who have been discharged from the hospital for 5-8 months. Methods: This study is a cross-sectional study of confirmed COVID-19 patients aged ≥18 years who were discharged from hospitals in Wuhan from January to April 2020. The demographics, clinical features, and laboratory findings of the participants were collected from medical records in the hospital. The participants from the study completed an investigation of clinical sequelae, blood tests, a pulmonary function examination and an unarmed rehabilitation evaluation at Hubei Provincial Hospital of Traditional Chinese & Western Medicine. A group of volunteers who were free of COVID-19 and lived in Wuhan during the outbreak were recruited as the comparison group. Results: The average age of the 574 COVID-19 survivors was 57.7±11.4 years, and 348 (60.6%) survivors were female. The average number of days from the onset of symptoms was 241.79±16.16. The average number of days from discharge was 194.3±14.4. Clinical sequelae were common, including general symptoms (n=321, 55.9%), respiratory symptoms (n=265, 46.2%), digestive symptoms (n=84, 14.6%), nervous symptoms (n=75,13.1%) and psychosocial symptoms (n=201, 35%). A total of 190 (33.7%) survivors reported reduced exercise capacity. Through the results of pulmonary function examination, anomalies were noted in carbon monoxide diffusion capacity (DLCO)% in 110 cases (32.4%), maximal mid-expiratory flow (MMEF)% in 105 cases (30.7%), forced expired flow at 50% of forced vital capacity (FEF 50 )% in 128 cases (37.4%), and forced expired flow at 75% of forced vital capacity (FEF 75 )% in 240 cases (70.2%). The counts of T lymphocyte, CD4+ T lymphocyte counts, CD8+ T lymphocyte counts, B lymphocyte and NK cell in the survival group was significantly lower than that in the comparison group(all P 0.05). The T lymphocyte counts, CD4+ T lymphocyte counts and CD8+ T lymphocyte counts of the patients before discharge were significantly higher than those in the early stage of admission (P < 0.025). There were 319 (55.6%) survivors with positive or weakly positive IgG antibodies and 17 (2.9%) survivors with positive or weakly positive IgM antibodies. Conclusion: Even after 5 to 8 months of discharge, many survivors still have clinical sequelae, and some of them have impaired immune function. Therefore, the long-term rehabilitation of COVID-19 survivors remains a concern. Funding Statement: This study was funded by the National Key R&D Plan of China (2020YFC0841600), Guangdong Provincial Key Laboratory of Research on Emergency in TCM (2017B030314176), R&D plan in key areas of Guangdong Province (2020B1111300005), and National Administration of Traditional Chinese Medicine (2020ZYLCYJ05-11). Declaration of Interests: The authors declare that they have no competing interests. Ethics Approval Statement: This study was approved by the ethical committees of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China (GPHCM; No. BF2020-205-01). All participants signed informed consent forms.

Published
2020

14. Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life

Author

Liu, Yanfang, primary, Uemura, Hirotsugu, additional, Ye, Dingwei, additional, Lee, Ji Y., additional, Chiong, Edmund, additional, Pu, Yeong-S., additional, Razack, Azad H.A., additional, Pripatnanont, Choosak, additional, Rawal, Sudhir, additional, Low, Grace K.M., additional, Qiu, Hong, additional, Chow, Weng H., additional, and Van Kooten Losio, Maximiliano, additional

Published
2019
Full Text
View/download PDF

18. P0430 : Delta like ligand 4 drives liver damage through regulating chemokines

Author

Shen, Z., primary, Liu, Y., additional, Hu, J., additional, Park, O., additional, Feng, T., additional, Dewidar, B., additional, Xu, C., additional, Yu, C., additional, Li, H., additional, Augustin, H.G., additional, ten Dijke, P., additional, Gao, B., additional, Ebert, M.P.A., additional, Dooley, S., additional, Li, Y., additional, and Weng, H., additional

Published
2015
Full Text
View/download PDF

27. 381 DLL4 AND JAGGED-1 PROVIDE OPPOSING EFFECTS IN LIVER FIBROSIS

Author

Liu, Y., primary, Shen, Z., additional, Xu, M.-Y., additional, Meyer, C., additional, Müller, A., additional, Munker, S., additional, Li, Q., additional, Ilkavets, I., additional, Stump, C., additional, Müllenbach, R., additional, Zimmer, V., additional, Lammert, F., additional, Mertens, P.R., additional, Li, J., additional, Li, Y.-M., additional, Lu, L.-G., additional, Dooley, S., additional, and Weng, H.-L., additional

Published
2012
Full Text
View/download PDF

33. 105 NOTCH SIGNALING PLAYS A CRITICAL ROLE IN EXPERIMENTAL AND HUMAN LIVER FIBROGENSIS

Author

Dooley, S., primary, Liu, Y., additional, Ilkavets, I., additional, Shen, H., additional, Zimmer, V., additional, Bohle, R.M., additional, Zhu, C., additional, Xu, C., additional, Yu, C., additional, Meyer, C., additional, Ciuclan, L., additional, Stump, C., additional, Müller, A., additional, Huang, T., additional, Li, Y., additional, Lammert, F., additional, Singer, M.V., additional, Mertens, P.R., additional, and Weng, H.-L., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results